Background: Colorectal cancer (CRC) is a common but largely preventable cancer. Although fecal immunochemical tests (FITs) detect the majority of CRCs, they miss some of the cancers and most advanced adenomas (AAs). The potential of blood tests in complementing FITs for the detection of CRC or AA has not yet been systematically investigated. Methods: We conducted a systematic review of performance of FIT combined with an additional blood test for CRC and AA detection versus FIT alone. PubMed and Web of Science were searched until June 9, 2017. Results: Some markers substantially increased sensitivity for CRC when combined with FIT, albeit typically at a major loss of specificity. For AA, no relevant increase in sensitivity could be achieved. Conclusion: Combining FIT and blood tests might be a promising approach to enhance sensitivity of CRC screening, but comprehensive evaluation of promising marker combinations in screening populations is needed.
Introduction
With approximately 1.4 million incident cases and 700,000 deaths annually, colorectal cancer (CRC) ranks third among men and second among women among the most common cancers globally. 1 Although the vast majority of all or distal CRCs and adenomas can be detected by colonoscopy or sigmoidoscopy, respectively, less-invasive screening tests are desirable. Inconvenience of bowel preparation and potential (albeit rare) complications 2 limit adherence to screening endoscopy. Furthermore, many countries lack the resources to offer colonoscopy as a primary screening test, 3 resulting in long waiting times. Fecal immunochemical tests (FITs) have substantially higher sensitivity for CRC at similar levels of specificity compared to guaiac-based fecal occult blood tests (gFOBTs). 4 FITs on average detect nearly 80% of CRCs, although a wide range of sensitivities has been reported (25%-100%). 5 Sensitivities for advanced adenomas (AAs) are more limited, typically ranging from 20% to 30% and rarely exceeding 40%. 6 Because most CRCs develop slowly through the adenoma-carcinoma sequence 7 and are in principle preventable via removal of detected adenomas, improved AA sensitivity could reduce CRC incidence.
Blood (serum, plasma) tests appear to be more acceptable for screening participants than colonoscopy. 8 Many studies have assessed their potential as diagnostic tests for CRC screening, 9 but for none of them diagnostic performance equivalent to or better than performance of FIT 5 could be validated. However, combining the most promising tests with FIT might enhance diagnostic performance of FIT. To assess whether combining FIT and blood markers yields better sensitivity and/or specificity than individual testing with FIT, we systematically reviewed diagnostic studies reporting on diagnostic accuracy of FIT alone and combined with a blood marker test.
Methods

Data sources and search strategy
MEDLINE and Web of Science were searched for English-language articles from inception to June 9, 2017 . The search terms (see Supplement) covered expressions for FIT, advanced colorectal neoplasms and diagnostic accuracy measures. Reference lists of relevant articles were also screened. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 10 
Study selection methods
Eligible studies had to provide quantitative information on sensitivity and specificity or sufficient information to calculate them, and/or the area under the ROC curve (AUC/c statistic) for detection of CRC, AA or any advanced neoplasm (AN), and examine these outcomes for FIT alone and for the combination of FIT and a blood (serum/plasma) test. Non-AAs and ''any adenomas'' (advanced and non-advanced) were not investigated, because only a small minority of non-AAs are expected to develop into CRC. 11 To rule out verification bias, 12 we required conduction of colonoscopy as the gold standard for detecting colorectal neoplasms in all included participants.
Data extraction
Two authors (TN and KW) independently extracted data on study characteristics and outcomes from relevant articles. [13] [14] [15] [16] [17] [18] [19] [20] Eventual discrepancies were resolved by consensus. Sensitivities were extracted separately for CRC and AA. Sensitivities were calculated as the share of CRCs or AAs detected by FIT, the blood test or their combination. Specificities were defined as the share of participants with a negative result of FIT, the blood test or both combined among all individuals without AN.
Risk of bias in individual studies
Two authors (TN and KW) independently evaluated the risk of bias in the included studies with elements of the QUADAS-2 instrument 21 and the Cochrane Collaboration's tool 22 that we deemed most important for our study question.
Data analysis
The combinations of two tests can be interpreted as positive if one out of two tests is positive, whereas the other one may be negative (''pn''), or if both tests are positive (''pp''). If 2 Â 2 tables with true and false positives for both tests and their combinations were provided or reproducible, sensitivities and specificities for both interpretations were calculated. 15, 17 For one study, 17 ''ROC-like plots'' were created using R 23 and the ''mada'' package 24 to visualize diagnostic performance of the numerous reported test combinations. Figure 1 shows the study selection process. Of 2054 unique articles, 26 were given full text assessment and eight of them were included in our systematic review. [13] [14] [15] [16] [17] [18] [19] [20] The 18 articles excluded after full-text review did not report sensitivities and specificities for FIT combined with a blood test. Among the suitable articles, one 16 was entirely based on an asymptomatic CRC screening population. Two reports 13, 14 comprised participants from a prospective screening study and additionally recruited cases from a case-control study. Two articles 19, 20 are apparently based on the same asymptomatic CRC screening population comprising first-degree relatives of CRC patients with the same FIT but different blood markers examined. Two studies used a case-control design. 15, 18 One report 17 was based on a prospective study among symptomatic participants.
Results
Study selection
Blood markers added to FIT
Among the eight studies examining the performance of FIT alone in comparison to FIT combined with at least one blood marker, three 14, 15, 18 examined methylation at the Septin9 gene and one study 13 examined a panel consisting of the inflammatory markers C-reactive protein (CRP), serum CD26 (sCD26), complement C3a anaphylatoxin, and tissue inhibitor of metalloproteinases 1 (TIMP-1). One study 16 examined a panel comprising carcinoembryonic antigen (CEA), ferritin, seprase, osteopontin and anti-p53 antibody. One study 17 investigated BCAT1 and IKZF1 DNA methylation. The studies conducted in first-degree relatives of CRC patients 19, 20 examined FIT plus sCD26 19 and nucleoside diphosphate kinase A (NDKA). 20 
Study characteristics
Age and sex distribution, number of participants and country of study conduction are presented in Table 1 for studies comprising participants from the general population [13] [14] [15] [16] [17] [18] and in Table 2 for studies among first-degree relatives of CRC patients. 19, 20 All reports were published between 2012 and 2016. Studies were conducted in Germany, 13, 16 the United States of America (USA), 14 Australia, 17 China, 15 Taiwan 18 and Spain. 19, 20 Case numbers ranged from four to 179 for CRC and from 26 to 419 for AA. Three studies 13, 14, 16 
Conducted solely in a screening setting (16) Conducted in a screening setting, but additional inclusion of clinically detected CRC cases (13, 14) Conducted in asymptomatic firstdegree relatives of CRC patients (19, 20) Comprising controls and symptomatic cases (15, 18) Symptomatic cohort (17) Figure 1 . Flow diagram of study selection. focused on individuals aged 50 14, 16 or 55 13 and older, whereas the other studies either included younger participants 15, 17, 19, 20 or did not report an age range. 18 All studies examining AAs defined them as adenomas matching at least one of the following criteria: size !1 cm, high-grade dysplasia, adenomas with villous components. One study 17 also counted cases with !2 tubular adenomas as AA, and two studies 17, 19 included intramucosal carcinomas (stage-0 cancers) as AA. FIT manufacturers and FIT cutoffs are reported in the Supplementary Table.
Results of the study quality assessment
The results of our assessment of risk of bias across studies are summarized in Table 3 . Included studies were of moderate quality, with a median of three out of seven fulfilled criteria. Three studies were conducted in asymptomatic participants; of these, one was based on an average-risk screening population and two were based on asymptomatic first-degree relatives of CRC patients. The other studies, at least in part, comprised clinically detected CRC cases. The proportions of early stage CRCs (Union for International Cancer Control (UICC) 0, I or II, or Duke's A or B) ranged between 45% and 75% across studies (Supplementary Table) . Individuals had an age range of 20-84 years.
Data synthesis
A meta-analysis was not conducted, because the studies investigating the same marker combination were heterogeneous regarding study population characteristics and other potentially influential factors. Consistently, studies investigating sensitivities at fixed specificities found minor sensitivity gains. In a ''pn'' approach, sensitivity gains were seen only at the cost of specificity. The opposite was observable in studies reporting a ''pp'' combination.
Septin9
Of the three studies examining Septin9, 14,15,18 two 15, 18 were conducted in a clinical setting and one 14 used screening-identified cases and controls. Septin9 partly showed sensitivities and specificities similar to FIT across all studies, with large variation (Table 1) . Sensitivity of Septin9 for CRC ranged from 47% to 75%. Although some studies 14, 15 reported large sensitivity gains by combining FIT and Septin9 (>30 percentage points, reaching 89% 14 and 94% 15 sensitivity for CRC), increased sensitivity was achieved only at decreases in specificity (in ''pn'' combination) and vice versa (in ''pp'' combination). No study indicated a sensitivity gain larger than the loss in specificity or a specificity gain at only a modest loss in sensitivity. Evidence of the complementary value in AA detection 
SCR: study conducted solely in a screening setting (asymptomatic individuals undergoing colonoscopy); CAS: comparable distribution of both, age and sex among cases and controls (<10% difference in average proportions of sexes, up to 10 years' difference between cases and controls; ''þ'' if both age and sex distribution are comparable, otherwise ''-''); RRP: clear reporting of the study recruitment process with numbers and reasons of exclusions, ideally in a flow-chart; DCC: clear description of data collection and conduction of FIT; IET: independent examination of the index tests and the gold standard test (laboratory staff members who evaluated FIT and/or the blood test(s) were blinded to colonoscopic findings or endoscopists were blinded to the results of FIT and/or the blood test(s), whichever test was conducted first); PSC: marker cutoffs pre-specified in quantitative FIT (any qualitative FIT was rated as ''prespecified'' because no overoptimistic results can occur, in contrast to studies that optimize the AUC without splitting the data in a training and a test set. Adjusting cutoffs to a level yielding a fixed specificity was also rated as ''prespecified''); DAA: study provided a common definition of advanced adenomas ((tubulo- compared to FIT alone was limited to one study 15 reporting an increase from 29% to 43% sensitivity, while specificity decreased from 88% to 65%.
sCD26 and NDKA sCD26 as a single marker added to FIT was examined in a study among first-degree relatives of CRC patients. 19 Sensitivity for advanced neoplasia with FIT achieved by combining it with sCD26 in a ''pn'' approach could be increased from 37% to 56% and 65%, depending on the sCD26 cutoff. Specificity decreased from 98% to 94% and 89%, respectively ( Table 2 ). The positive likelihood ratios diminished compared to FIT alone, indicating no overall improvement. Adding NDKA to FIT 20 yielded higher sensitivities than FIT alone, but gains were smaller compared to adding sCD26. Sensitivity increases by the ''pn'' approach were large in proximal AAs (from 7% to 29%), but smaller in distal AAs (from 41% to 51%). In contrast to the study on combined performance of FIT and sCD26, 19 that marker had 0% sensitivity for CRC at 97.7% specificity in a multi-marker panel. 13 
Multi-marker panels
One study 17 combined the DNA methylation markers BCAT1 and IKZF1 in a ''pn'' approach and the resulting combination with FIT in both a ''pn'' and ''pp'' approach for CRC and AA, each at three different FIT cutoffs. Graphical presentation of sensitivity versus 1-specificity in ''ROC-like plots'' (Figure 2 ) demonstrates small overall gains with the addition of the blood test. For CRC, ''pn'' combinations with higher FIT cutoffs seemed to yield a marginally higher sensitivity at no loss in specificity, compared to FIT alone. However, the minor differences might be due to chance. No strong stage-dependence was seen for the blood test.
In a study examining FIT combined with five blood markers, 16 sensitivity for CRC and AA rose from 78% to 83% and from 28% to 35%, respectively, although CIs widely overlapped (Table 1) . Specificity decreased from 96% for FIT alone to 92%. That study used a predefined algorithm trained on data of a previous study to avoid overfitting. Based on the same study, a previous report focusing on AA 13 found virtually no increases in sensitivity at constant 98% specificity when adding TIMP-1 alone or together with CRP and sCD26. The likelihood ratio tests nevertheless indicated a significant improvement in the AUC (p ¼ 0.002 for TIMP-1 and p ¼ 0.0007 for all three blood markers). Absolute increases in the AUC were between three and five percentage points.
Discussion
We summarized the available evidence from studies evaluating sensitivity and specificity of FIT combined with blood markers for CRC or AA detection. Most studies did not find large improvements in FIT performance in such combinations, neither for CRC nor for AA. Sensitivity gains were achieved only at decreased specificity and vice versa. The only study comparing sensitivities for AA at fixed specificities 13 found virtually no gain in sensitivity. One study 17 demonstrated the methodological challenges for comparing combined diagnostic tests by providing a wide range of results for possible marker combinations.
Studies examining diagnostic performance of blood markers for CRC detection were systematically reviewed already. 9, 25, 26 However, these studies did not examine their test performance when combined with FIT. Liu et al. 9 waived a conclusion on which biomarker to recommend, whereas Shah et al. 25 highlighted the promising results of DNA hypermethylation markers, specifically Septin9 expression and other DNA and microRNA (miRNA) panels. A meta-analysis 26 yielded 75% sensitivity and 89% specificity of Septin9 for CRC detection. Other markers had sensitivities ranging from 54% to 74% and specificities between 85% and 93%. However, these markers were not yet evaluated in an asymptomatic CRC screening population. One study 27 evaluated Septin9 (without FIT) prospectively in a CRC screening population with colonoscopy as the reference standard. With 91.5%, specificity was comparable to that of FIT. Sensitivity was only 48.2% for CRC, though, and 11.2% for AAs, which was similar to the false-positive rate (9.1%). By comparison, FIT was examined in screening studies and achieved 79% sensitivity for CRC and 94% specificity. 5 Our study has several strengths. This is the first systematic review investigating diagnostic performance of a combination of FIT and blood (serum, plasma) tests. Two authors extracted data independently. All studies verified test results with colonoscopy. We adhered to the PRISMA statement 10 and searched two databases and references of included articles. Information on potentially influential study characteristics was considered. Finally, most included studies were of moderate-to-high quality.
Our study also has limitations. We focused on Englishlanguage articles. The number of suitable articles was small and few studies investigated the same marker combination. Publication and reporting bias are conceivable. Blood tests in general are unable to detect AAs, 16 limiting their potential for CRC prevention. Predominant clinical settings in included studies and diagnostic or therapeutic measures for CRC patients might have influenced blood marker levels. Clinically detected CRC cases may present with more advanced, more easily detectable 14, 28 stages than in screening settings. 29 Thereby, potential ''spectrum effects'' might have led to some overestimation of sensitivities and specificities compared to a screening setting. 30 Only one study investigated diagnostic performance of a CRC blood marker combined with FIT in a screening population. 16 Future studies evaluating CRC blood markers in screening settings should additionally investigate the performance of a combination with FIT and of FIT alone. When combining FIT and blood markers, studies should examine sensitivity at equal specificities through cutoff adjustments. Ideally, performance over multiple cutoffs of FITs, blood tests or both tests using ROC approaches should be evaluated. Studies examining multi-marker panels might investigate if restricting the number of investigated markers would lead to comparable results, thereby facilitating application in clinical practice and improving cost-effectiveness. For example, one study 13 evaluated a combination of five different blood markers, one of which (sCD26) had 0% sensitivity for CRC at the observed specificity, probably making that marker expendable.
To be suitable for mass screening, serum/plasma markers should not only improve diagnostic accuracy compared to FIT alone. Further requirements are ease of conducting the test (e.g. requiring small amounts of blood), marker stability and reproducibility. For costeffectiveness, a combined FIT and serum or plasma test should maintain high specificity. Microsimulation models might help to compare cost-effectiveness of the numerous possible screening methods comprising FIT and/or one or several blood tests. Such models should incorporate screening adherence rates, which may strongly affect cost-effectiveness. 31 Septin9, for instance, costs approximately 150 US$ per test 32 and studies indicate a significantly decreased specificity in a ''pn'' interpretation of a combination with FIT.
In conclusion, available evidence suggests very limited gain by combining currently available blood tests for CRC or AA detection with FIT compared to either test alone. The poor AA detection even when combining FIT and blood tests limits their ability to prevent CRC through early detection and removal of AAs. However, blood markers for CRC or AA detection are an emerging field and many markers available to date 9 have not yet been examined in combination with FIT.
